Loading data for ANL — first visit, this takes a few seconds.
Adlai Nortye Group Ltd. (ANL)
NasdaqGM: ANL
· Real-Time Price · USD
13.82
-0.50 (-3.49%)
At close: Aug 28, 2026, 8:00 PM
13.82
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Adlai Nortye Group Ltd. (ANL) Stock Price, Analysis & Data
-3.49% (1D)
No data available
| Bid | 9.29 |
| Market Cap | 889.98M |
| Revenue (ttm) | 18.06M |
| Net Income (ttm) | -22.53M |
| 1.12 | |
| -0.64 | |
| n/a | |
| -47.11 | |
| P/B (ttm) | 4.14 |
| P/S (ttm) | 49.29 |
| Earnings Date | n/a |
| Ask | 16.89 |
| Volume | 165,027 |
| Avg. Volume (20D) | 180,200 |
| Open | 14.41 |
| Previous Close | 14.32 |
| Day's Range | 13.53 - 14.45 |
| 52-Week Range | 0.88 - 17.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANL
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunothera...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 29, 2023
Employees 109
Stock Exchange NasdaqGM
Ticker Symbol ANL
Website https://www.adlainortye.com
Financial Performance
In 2025, Adlai Nortye's revenue was 5M, an increase of undefined% compared to the previous year's 0. Earnings were -35.53M, a decrease of -31.5%.
Financial Statements
Page 1 of 2